Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals’ (MXC) first bulk shipment of CogniCann is en route to Australia and will arrive in the upcoming days
  • The first shipment will allow the commencement of the phase IIb clinical trials in partnership with the University of Notre Dame in Western Australia
  • The trial will involve 50 patients aged 65 and over, testing the effects of CogniCann on dementia and Alzheimer’s patients
  • MGC’s share price is currently 1.61 per cent with shares trading for 3.2 cents apiece

MGC Pharmaceuticals’ (MXC) first bulk shipment of CogniCann is en route to Australia and will arrive in the upcoming days.

This shipment also includes units for commercial prescriptions under the Special Access Scheme or by authorised prescribers in Australia.

The first shipment will allow the commencement of the phase IIb clinical trials in partnership with the University of Notre Dame in Western Australia.

This study will involve 50 patients aged 65 and over, testing the effects of CogniCann on dementia and Alzheimer’s disease patients.

“The first shipment which will enable the commencement of phase IIb clinical trial of CogniCann in Australia is another positive step for us,” Co-founder and Managing Director Roby Zomer commented.

“CogniCann has the potential to seriously alleviate the symptoms of patients living with Alzheimer’s disease and dementia,” he added.

The study will assess the best dose of drug in regard to its effectiveness and safety in targeting symptoms associated with dementia and Alzheimer’s.

While it is not a specific disease, dementia is a group of conditions characterised by the impairment of at least two brain functions, most commonly memory loss and judgement.

Some medications and therapies may help manage the symptoms are some causes are reversible.

Alzheimer’s is a physical brain disease that causes dementia, resulting in impaired memory, thinking and behaviour.

While treatments such as physical exercise, cognition-enhancing medication and specialists may help no cure currently exists but these treatments may temporarily improve symptoms.

MGC Pharma’s share price is up a slight 1.61 per cent with shares trading for 3.2 cents apiece at 11:45 am AEDT.

MXC by the numbers
More From The Market Herald

" Zelira Therapeutics (ASX:ZLD) releases HOPE trial data

Zelira Therapeutics’ (ASX:ZLD) latest trial results have shown patients with ASD achieved moderate therapeutic effect while…

" Nyrada (ASX:NYR) edges closer to European patent for cholesterol management drug

Nyrada Inc (NYR) has received a Notice of Intention from the European Patent Office (EPO) to…
Hydrix (ASX:HYD) - Executive Chairman, Gavin Coote

" Hydrix (ASX:HYD) signs partnership with Scandinavian Realheart to develop Total Artificial Heart

Hydrix (ASX:HYD) has signed a long-term partnership agreement with Scandinavian Realheart, a Swedish company developing the…

" Incannex Healthcare (ASX:IHL) receives new FDA advice for sleep apnoea treatment

Incannex Healthcare (ASX:IHL) has been given fresh guidance from the US Food and Drug Administration (FDA)…